Tianjin Medical University Cancer Institute and Hospital: Cholangiocarcinoma trials

The registry lists 13 Cholangiocarcinoma studies with Tianjin Medical University Cancer Institute and Hospital as lead sponsor. 8 are open to participants now and 0 have results posted.

Phase 2 10Phase 3 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICCNot yet recruitingNCT07432568Phase 2
• Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder CancerRecruitingNCT06852287Phase 2
• Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic CholangiocarcinomaRecruitingNCT06721286Phase 2
• TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant TumorsRecruitingNCT06487663Not applicable
• A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCCNot yet recruitingNCT06375642Phase 2
• Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence RiskRecruitingNCT05672537Phase 2
• Second Line Therapy for Advanced Intrahepatic CholangiocarcinomaNot yet recruitingNCT05535647Phase 2
• GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced CholangiocarcinomaRecruitingNCT05215665Not applicable
• Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic CholangiocarcinomaActive, not recruitingNCT07646717Phase 2
• Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract CancerActive, not recruitingNCT06717464Phase 2
• Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.Status unknownNCT05620498Phase 2
• Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic CholangiocarcinomaStatus unknownNCT05251662Phase 2
• Adjuvant Chemotherapy for Biliary Tract Cancer After Curative ResectionStatus unknownNCT03779035Phase 3